RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts

 RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts

PR Newswire

MARLBOROUGH, Mass., July 2, 2014

MARLBOROUGH, Mass., July 2, 2014 /PRNewswire/ --RXi Pharmaceuticals
Corporation (NASDAQ: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, today announced the official
opening of its new office and laboratory in the Marlborough Technology Center.
The Company will host a ribbon-cutting ceremony on Wednesday, July 9, 2014
from 10:00 -12:00 p.m., at 257 Simarano Drive, Marlborough, MA, to mark the
opening of their new facility. The ceremony will be held in collaboration
with the Massachusetts Life Sciences Center (MLSC) and MassBio.

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

"The Company's recent move to Marlborough has allowed us to centralize our
employee base," said Dr. Geert Cauwenbergh, President and CEO of RXi
Pharmaceuticals. "In addition, this facility allows for future growth
considerations as we advance our pre-clinical and clinical programs."

RXi Pharmaceuticals was founded in 2011. Since that time, the Company has
successfully completed and announced positive results from two Phase 1
clinical studies with our lead compound RXI-109. We have formed two
therapeutic franchises, within RXi, based on our areas of focus: Dermatology
and Ophthalmology. The Company has continued to progress its dermal clinical
program and is currently conducting two Phase 2 studies with a third study
planned for initiation this year. Within our Ophthalmology program, we have
obtained positive results, with RXI-109, in the eyes of cynomolgus monkeys. In
addition, the Company received a notice of allowance from the United States
Patent and Trademark Office (USPTO) for a key patent covering our core,
self-delivering RNAi technology (sd-rxRNA®) platform, which sets us apart from
the competition and provides us with a powerful advantage to deliver our RNAi
compounds without delivery vehicles. We believe we are well positioned for
continued success.

The Company is supported by a group of dedicated, professional employees, with
strategic guidance provided by a seasoned and successful Board of Directors,
and by an accomplished Management and Scientific Advisory Board with
significant experience in RNAi therapeutics, dermatologydrug development and
in building and managing emerging life science companies.

"Thanks to our growth strategy of investing in education, innovation and
infrastructure, Massachusetts continues to lead the world in life sciences,"
said Massachusetts Governor Deval Patrick. "We congratulate RXi
Pharmaceuticals on their expansion and look forward to their continued
contributions to our thriving life sciences community."

"On behalf of the Center, I would like to extend our warmest congratulations
to RXi Pharmaceuticals as the company officially opens its new office and
laboratory in Marlborough," said Susan Windham Bannister, Ph.D., President and
CEO of the Massachusetts Life Sciences Center, the agency charged with
implementing Governor Patrick's 10-year, $1 billion Life Sciences Initiative.
"We've enjoyed a long-standing relationship with RXi, and we are pleased to
celebrate its ongoing success and growth in Massachusetts."

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that
supports life sciences innovation, research, development and
commercialization. The MLSC is charged with implementing a 10-year,
$1-billion, state-funded investment initiative. These investments create jobs
and support advances that improve health and well-being. The MLSC offers the
nation's most comprehensive set of incentives and collaborative programs
targeted to the life sciences ecosystem. These programs propel the growth that
has made Massachusetts the global leader in life sciences. The MLSC creates
new models for collaboration and partners with organizations, both public and
private, around the world to promote innovation in the life sciences. For
more information, please visit www.masslifesciences.com.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company
focused on discovering, developing and commercializing innovative therapies
based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform.
Therapeutics that use RNA interference, or "RNAi," have greatpromise because
of their ability to down-regulate the expression of specific genes that may be
over-expressed in disease conditions. Building on the pioneering work of
scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109,
entered into human clinical trials in June 2012 and is currently being
evaluated in Phase 2 clinical trials to reduce dermal scarring (fibrosis).
RXI‑109 targets connective tissue growth factor (CTGF), which may also be key
in the development of retinal scarring.RXi's sd‑rxRNA oligonucleotides are
designed for therapeutic use and have drug-like properties, such as high
potency, target specificity, serum stability, reduced immune response
activation, and efficient cellular uptake. These hybrid oligonucleotide
molecules combine the beneficial properties of conventional RNAi and antisense
technologies. This allows sd‑rxRNAs to achieve efficient cellular uptake and
potent, long-lasting intracellular activity. For more information, please
visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation's products and
technologies. Forward-looking statements about expectations and development
plans of RXi's products involve significant risks and uncertainties: the risk
that we may not be able to successfully develop our candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed, risks related
to the development and commercialization of products by our competitors, the
risk related to our ability to control the timing and terms of collaborations
with third parties, and the possibility that other companies or organizations
may assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

For additional details or to attend the ceremony, please contact:

RXi Pharmaceuticals             MLSC

Tamara McGrillen                Angus McQuilken

Phone: 508-929-3646             Phone: 617-921-7749

Email: tmcgrillen@rxipharma.com Email: amcquilken@masslifesciences.com

RXi Pharmaceuticals' new facility is located at the following address:

257 Simarano Drive, Suite 101
Marlborough, MA 01572
Phone: 508-767-3861
Email: admin@rxipharma.com

This announcement is not intended to be a commercial endorsement by the MLSC
of any products or services provided or developed by the entities referenced
in this release.

SOURCE RXi Pharmaceuticals Corporation

Website: http://www.rxipharma.com
 
Press spacebar to pause and continue. Press esc to stop.